600085.SS
600085.SS
CNE000000R69
BEIJING TONG REN TANG CO
Loading chart...

Company Profile

Beijing Tongrentang Co., Ltd engages in the production and sale of traditional Chinese medicine preparations in China and internationally. The company offers various product dosage forms, such as pills, powders, medicated wines, capsules, oral liquids, and drop pills. Its products are used for cardiovascular, cerebrovascular, gynecology, heat-clearing, respiratory system, nourishing and calming, digestive, pediatrics, wind-dispelling and dampness removing, orthopedics, facial features, dermatological surgery, mental health, and food and beverages applications. The company was founded in 1997 and is based in Beijing, China. Beijing Tongrentang Co., Ltd operates as a subsidiary of China Beijing Tong Ren Tang Group Co. Ltd.

Related stocks

000423.SZ
000423.SZ • China
DEEJ
46.68 CNY
4.47B USD 1Y -1.3%
688192.SS
688192.SS • China
DIZAL PHARMACEUTICAL CO LTD
59.95 CNY
4.17B USD 1Y -15%
000999.SZ
000999.SZ • China
CR SANJIU
24.82 CNY
6.18B USD 1Y -12.3%
000513.SZ
000513.SZ • China
LIVZON GROUP
30.5 CNY
4.05B USD 1Y -21.4%
000963.SZ
000963.SZ • China
HD MEDICINE
27.29 CNY
7.16B USD 1Y -34.6%
600566.SS
600566.SS • China
HUBEI JUMPCAN PHARMACEUTICAL CO
26.7 CNY
3.68B USD 1Y +8.3%
002294.SZ
002294.SZ • China
SALUBRIS
30.93 CNY
5.16B USD 1Y -46.6%
600521.SS
600521.SS • China
ZHEJIANG HUAHAI PHARMACEUTICAL
17.45 CNY
3.91B USD 1Y -16.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
32.6% p.a.
Max Drawdown (5Y)
-64.3%
Sharpe Ratio (5Y)
-0.24
Beta Factor
0.03
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (32.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -64.3% in the extended horizon.
ende